NCT06561932招募中不适用
A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 8
- 主要终点
- Bi-Ventricular capture on 12 lead EKG
研究概览
简要总结
Assess the safety and efficacy of the co-implantation of the WiSE CRT System with an intracardiac pacemaker to provide totally leadless CRT.
详细描述
The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
Single-arm, prospective, multicenter, observational study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with a class I or IIa (1) or (2) indication for implantation of a CRT device according to current available guidelines 1,2,4 (with additional QRS criteria on Class IIa (1)):
- •Class I: NYHA II, III, IV, EF ≤ 35%, LBBB, QRS ≥ 150 ms
- •Class IIa (1): NYHA II, III, IV, EF ≤ 35%, LBBB, QRS ≥ 130 to < 150 ms
- •Class IIa (2): NYHA II, III, IV, EF ≤ 35%, non-LBBB, QRS ≥ 150 ms
- •Patient or legally authorized representative can provide written authorization and/or consent per institution requirements
- •Male or Female, aged 22 years or above
- •Meets criteria for one of the two patient groups
- •Group A: De novo totally leadless CRT implant in whom the physician believes a totally leadless approach would be beneficial (e.g., wish to avoid lifelong transvenous lead implant, anatomical constraints, history of device infection).
- •Patients with symptomatic AF and an uncontrolled heart rate who are candidates for AV node ablation (irrespective of QRS duration and LVEF), and in whom the physician believes a leadless pacing approach would be beneficial.
- •Patients with high degree AV block who have an indication for permanent pacing (with a LVEF ≤ 50%), are expected to require ventricular pacing more than 40% of the time, and in whom the physician believes a leadless approach would be beneficial.
- •Group B: Upgrade chronic intracardiac pacemaker to CRT
- •Patients with existing intracardiac pacemakers with greater than 20% RV pacing, who have developed symptomatic HF.
排除标准
- •Patient who is or is expected to be inaccessible for follow-up visits
- •Female participant who is pregnant, lactating, or planning pregnancy during the course of the study
- •Inability to comply with the study follow-up or other study requirements
- •History of chronic alcohol/ drug abuse and currently using alcohol/ drugs
- •Non-ambulatory (or unstable) NYHA class 4
- •Life expectancy less than 12 months
- •Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- •Patient who is enrolled in another clinical study that could confound the results of this study (Note: patients enrolled in complementary study are eligible for enrolment)
研究组 & 干预措施
Single-arm, prospective, multicenter, observational study.
Experimental
.WiSE System therapy ON with Guideline Directed Medical Therapy
干预措施: WiSE CRT System (Device)
结局指标
主要结局
Bi-Ventricular capture on 12 lead EKG
时间窗: 1 month and 6 months
Performance
Incidence of Device and procedure related complications.
时间窗: 1 month and 6 months
Primary Safety
次要结局
- Change in ejection fraction (EF) from Baseline(6 months)
- Change in Six-minute walk test(6 months)
- Change in NYHA class(6 months)
- Change in in left ventricular end systolic volume (LVESV)(6 months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Wireless Stimulation Endocardially for Cardiac Resynchronization TherapyVentricular DysfunctionHeart FailureCardiomyopathyNCT01294527EBR Systems, Inc.17
进行中（未招募）
不适用
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade PatientsHeart FailureNCT02922036EBR Systems, Inc.300
尚未招募
不适用
In Silico Pace Mapping To Optimise Ventricular Tachycardia AblationVentricular TachycardiaNCT05500365Guy's and St Thomas' NHS Foundation Trust25
招募中
不适用
Intracardiac Echocardiography Guided Watchman Device ImplantLeft Atrial Appendage ThrombosisAtrial FibrillationNCT06007872The Cleveland Clinic100
Unknown
1 期
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic CardiomyopathyIschemic CardiomyopathyNCT01946048Hebei Medical University10